DongKook Pharmaceutical Co., Ltd. (KOSDAQ: 086450)

South Korea flag South Korea · Delayed Price · Currency is KRW
15,570
-50 (-0.32%)
Jan 22, 2025, 3:00 PM KST
-10.98%
Market Cap 686.79B
Revenue (ttm) 789.11B
Net Income (ttm) 61.64B
Shares Out 43.97M
EPS (ttm) 1,378.55
PE Ratio 11.33
Forward PE 10.41
Dividend 180.00 (1.17%)
Ex-Dividend Date Dec 27, 2023
Volume 57,356
Average Volume 96,838
Open 15,590
Previous Close 15,620
Day's Range 15,500 - 15,700
52-Week Range 14,990 - 20,600
Beta 0.60
RSI 40.73
Earnings Date Mar 7, 2025

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sell pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, and cosmetics. Its pipeline includes DKF-310, which is in preclinical trials for the treatment of dementia; DKM-413, used for anesthetic; DKF-361, used to treat hypertension; DKF-325, an anticoagulant; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, that is in clinical studies, indicated for benign prostat... [Read more]

Industry Pharmaceutical Preparations
Founded 1968
Employees 1,131
Stock Exchange KOSDAQ
Ticker Symbol 086450
Full Company Profile

Financial Performance

In 2023, DongKook Pharmaceutical's revenue was 730.99 billion, an increase of 10.48% compared to the previous year's 661.65 billion. Earnings were 47.18 billion, a decrease of -10.82%.

Financial Statements

News

There is no news available yet.